Vera Therapeutics, Inc. - Class A Common Stock (NQ:VERA)

48.91 +2.39 (+5.15%)

Streaming Delayed Price Updated: 3:29 PM EST, Jan 7, 2026 Add to My Watchlist

Price and Volume

Volume	746,578
Open	47.72
Bid (Size)	48.91 (200)
Ask (Size)	48.99 (600)
Prev. Close	46.52
Today's Range	47.34 - 50.79
52wk Range	18.53 - 56.05
Shares Outstanding	44,261,109
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy

Today 7:30 EST

From Vera Therapeutics

Via GlobeNewswire

Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock

December 09, 2025

From Vera Therapeutics

Via GlobeNewswire

Performance

YTD	+0.6%	+0.6%
1 Month	+8.6%	+8.6%
3 Month	+58.8%	+58.8%
6 Month	+112.7%	+112.7%
1 Year	+15.7%	+15.7%

More News

Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock

December 08, 2025

From Vera Therapeutics

Via GlobeNewswire

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 05, 2025

From Vera Therapeutics

Via GlobeNewswire

Why Vera Therapeutics Stock Rocked the Market on Tuesday ↗

December 02, 2025

Via The Motley Fool

Why Vera Therapeutics Stock Crushed it Today ↗

November 26, 2025

Via The Motley Fool

Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors

November 26, 2025

From Vera Therapeutics

Via GlobeNewswire

Get insights into the top gainers and losers of Tuesday's after-hours session. ↗

November 25, 2025

Via Chartmill

Vera Therapeutics to Participate at Upcoming Investor Conferences

November 24, 2025

From Vera Therapeutics

Via GlobeNewswire

Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit

November 10, 2025

From Vera Therapeutics

Via GlobeNewswire

Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy

November 07, 2025

From Vera Therapeutics

Via GlobeNewswire

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 07, 2025

From Vera Therapeutics

Via GlobeNewswire

Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine

November 06, 2025

From Vera Therapeutics

Via GlobeNewswire

10 Health Care Stocks Whale Activity In Today's Session ↗

November 05, 2025

Via Benzinga

VERA THERAPEUTICS INC (NASDAQ:VERA) Reports Q3 2025 Earnings, Misses EPS Estimates Amid Key Clinical Progress ↗

November 05, 2025

Via Chartmill

Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

November 05, 2025

From Vera Therapeutics

Via GlobeNewswire

Capricorn Fund Loads Up on Phreesia (PHR) With a 484,000 Share Purchase ↗

October 27, 2025

Via The Motley Fool

Vera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4:30 pm ET

October 22, 2025

From Vera Therapeutics

Via GlobeNewswire

Capricorn Buys New Stake in Ionis Pharmaceuticals (IONS) With 163,000 Shares ↗

October 20, 2025

Via The Motley Fool

Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025

October 17, 2025

From Vera Therapeutics

Via GlobeNewswire

Vera Therapeutics' Lead Kidney Drug Poised For 2026 Launch In Multi-Billion-Dollar Market ↗

October 16, 2025

Via Benzinga

This Celestica Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

October 16, 2025

Via Benzinga

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 10, 2025

From Vera Therapeutics

Via GlobeNewswire

6 Stocks Goldman Sachs Says Are Poised For Potential Acquisition In Next 12 Months — Including A Huge 200% Winner ↗

September 30, 2025

Via Benzinga

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 05, 2025

From Vera Therapeutics

Via GlobeNewswire

Frequently Asked Questions

Is Vera Therapeutics, Inc. - Class A Common Stock publicly traded?

Yes, Vera Therapeutics, Inc. - Class A Common Stock is publicly traded.

What exchange does Vera Therapeutics, Inc. - Class A Common Stock trade on?

Vera Therapeutics, Inc. - Class A Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Vera Therapeutics, Inc. - Class A Common Stock?

The ticker symbol for Vera Therapeutics, Inc. - Class A Common Stock is VERA on the Nasdaq Stock Market

What is the current price of Vera Therapeutics, Inc. - Class A Common Stock?

The current price of Vera Therapeutics, Inc. - Class A Common Stock is 48.91

When was Vera Therapeutics, Inc. - Class A Common Stock last traded?

The last trade of Vera Therapeutics, Inc. - Class A Common Stock was at 01/07/26 03:29 PM ET

What is the market capitalization of Vera Therapeutics, Inc. - Class A Common Stock?

The market capitalization of Vera Therapeutics, Inc. - Class A Common Stock is 2.17B

How many shares of Vera Therapeutics, Inc. - Class A Common Stock are outstanding?

Vera Therapeutics, Inc. - Class A Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.